Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00946335 · ClinicalTrials.gov registry record · Phase 1
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00946335: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00946335 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00946335, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of ABT-888 when given in combination with temozolomide in treating young patients with recurrent or refractory CNS tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving ABT-888 together with temozolomide may kill more tumor cells.
Interventions
- OTHER laboratory biomarker analysis
- DRUG temozolomide
- OTHER pharmacological study
- DRUG veliparib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-07 |
| Est. Completion | 2014-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00946335
The ClinicalTrials.gov registry entry for NCT00946335 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00946335 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00946335 about?
NCT00946335 is a clinical study titled "ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors". This phase I trial is studying the side effects and best dose of ABT-888 when given in combination with temozolomide in treating young patients with recurrent or refractory CNS tumors. ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in ch...
What is the current status of trial NCT00946335?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2009-07. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00946335?
The interventions under investigation include: laboratory biomarker analysis (OTHER), temozolomide (DRUG), pharmacological study (OTHER), veliparib (DRUG).
Who is sponsoring clinical trial NCT00946335?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.